Security key
74587V107
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI)
CUSIP: 74587V107
Q4 2016 13F Holders as of 31 Dec 2016
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 34,931,958
- Total 13F value
- $1,072,410,439
- Share change
- +5,015,740
- Put/Call ratio
- 32%
- SEC-reported price per share
- $30.70
- Number of holders
- 128
- Value change
- +$72,943,477
- Number of buys
- 80
- Number of sells
- 63
- Shares outstanding
- 49,633,071
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2016
Institutions
128
Top holders
10
PBYI full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2017
Previous quarter: Q3 2016
PUMA BIOTECHNOLOGY, INC. SEC filings
PUMA BIOTECHNOLOGY, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74587V107
Recent filing periods:
Ownership snapshot
Top reported holders of PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ADAGE CAPITAL PARTNERS GP...
Disclosed value leader
ADAGE CAPITAL PARTNERS GP...
Comparable rows
15/15
Latest evidence
30 Sep 2016
13F
Lead comparable stake: 11%
Showing 1-6 of 15 holder rows.
Quick read
ADAGE CAPITAL PARTNERS GP, L.L.C. leads the comparable SEC ownership view at 11%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ADAGE CAPITAL PARTNERS GP, L.L.C.'s linked filing trail.
Comparable ownership
Top 5
ADAGE CAPITAL PARTNERS GP, L.L.C.
11%
FMR LLC
9.8%
ORBIMED ADVISORS LLC
4.8%
JANUS HENDERSON INVESTORS US LLC
4.6%
VANGUARD GROUP INC
4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
Company
|
11%
|
$381,291,000
5,686,668 shares
|
— | 30 Sep 2016 |
| FMR LLC |
13F
Company
|
9.8%
|
$326,799,000
4,873,963 shares
|
— | 30 Sep 2016 |
| ORBIMED ADVISORS LLC |
13F
Company
|
4.8%
|
$159,815,000
2,383,525 shares
|
— | 30 Sep 2016 |
| JANUS HENDERSON INVESTORS US LLC |
13F
Company
|
4.6%
|
$153,395,000
2,287,774 shares
|
— | 30 Sep 2016 |
| VANGUARD GROUP INC |
13F
Company
|
4%
|
$134,368,000
2,003,986 shares
|
— | 30 Sep 2016 |
| Point72 Asset Management, L.P. |
13F
Company
|
2.1%
|
$68,975,000
1,028,706 shares
|
— | 30 Sep 2016 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2016
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
128
Shares
34,931,958
Rows available
128
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2016 vs Q3 2016 Across Filers
Q3 2016 holders
145
Q4 2016 holders
128
Holder diff
-17
| Investor | Q3 2016 Shares | Q4 2016 Shares | Share Diff | Share Chg % | Q3 2016 value | Q4 2016 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend